Ebenbuild

Founders, Backgrounds, and Bench

Ebenbuild was founded in 2019 by a team of four co-founders, including Professor Wolfgang Wall, the founding director of the Institute for Computational Mechanics at the Technical University of Munich (TUM). The team combines expertise in computational biomechanics, AI, and software engineering to translate academic research into clinical applications.

Company Overview

Ebenbuild GmbH was founded in Munich in 2019, emerging directly from academic research at the Technical University of Munich (TUM) [tum.de, 2026]. The company was established by four co-founders to translate years of research in computational biomechanics into clinical applications [tum.de, 2026].

Its initial focus was on developing patient-specific digital twin models of the lungs, a technology that was validated in a peer-reviewed study published in Nature Communications Medicine in 2024 [BioWorld, 2026]. The company secured its first institutional funding in March 2022, a €2.5 million seed round led by Bayern Kapital with participation from High-Tech Gründerfonds (HTGF) [VC Magazin, 2026]; [Munich Startup, 2026]; [BioM, 2026]. This was followed by significant non-dilutive grants, including up to €900,000 from the German Federal Ministry of Education and Research (BMBF) in 2024 and a €2.3 million grant from the European Innovation Council (EIC) in July 2025 [BioM, 2026]; [Munich Startup].

Data Accuracy: GREEN -- Company founding and major funding rounds confirmed by multiple independent sources including Munich Startup, BioM, and VC Magazin. The EIC grant is reported by Munich Startup. The BMBF grant figure is confirmed by BioM.

The Product and the Stack

Ebenbuild’s product is a software platform that generates patient-specific digital twin models of the lungs, a process that begins with standard medical imaging. The company’s public materials state the software ingests a patient’s CT scans and clinical data to create a high-fidelity, physics-informed model of the individual’s respiratory system [LinkedIn]. The underlying technology integrates computational fluid dynamics and tissue mechanics with AI to simulate lung function, airflow, and the mechanical forces exerted during ventilation [mtec-sc.org].

The platform serves two distinct but related application surfaces. For clinical use, it is positioned as an ICU decision-support tool for managing mechanical ventilation in patients with Acute Respiratory Distress Syndrome (ARDS). The software provides personalized ventilation settings and treatment recommendations aimed at minimizing ventilator-induced lung injury [htgf.de]. For pharmaceutical research, the same digital twin technology is used to conduct in-silico trials, simulating cohorts of virtual patients to study pulmonary drug delivery and efficacy, such as in pulmonary fibrosis [mtec-sc.org].

A key differentiator is the platform’s validation in peer-reviewed research. A study published in Nature Communications Medicine, co-authored by Ebenbuild’s scientific founders, demonstrated the technology could predict inhaled drug deposition across the entire human lung with high spatial resolution, showing excellent agreement against in vivo clinical imaging data [BioWorld, 2026] [Mirage News, 2026].

Data Accuracy: YELLOW -- Core funding and team facts are corroborated by multiple sources; some product claims and market sizing rely on company statements.

Market Opportunity

Ebenbuild operates at the intersection of two distinct but related markets: clinical decision support systems (CDSS) for intensive care and in-silico trial platforms for pharmaceutical development.

Metric	Value
Clinical Decision Support Systems (CDSS)	$4.5B (2023)
CDSS Projected	$10.5B (2032)
Digital Twins in Healthcare	$1.6B (2024)
Digital Twins Projected	$21.1B (2034)

Data Accuracy: YELLOW -- Market sizing for Ebenbuild's specific offering is based on a single, unverified company statement. Adjacent market figures are drawn from third-party analyst reports.

The Competitive Field

Ebenbuild operates in a specialized niche where direct, head-to-head competitors are not yet publicly named, but the company faces a landscape of established incumbents, adjacent substitutes, and emerging challengers across its two target markets. In the clinical decision support system (CDSS) market for ICU ventilation, the primary alternatives are established protocols and guidelines embedded in ventilator hardware and clinical workflows. Companies like Dräger, Getinge, and Medtronic dominate the ventilator market itself. For pharmaceutical in-silico trials, the competitive set includes large simulation software providers like Ansys and Siemens Healthineers, as well as specialized computational biology firms.

Data Accuracy: YELLOW -- Competitive analysis is inferred from market segments and adjacent players; no direct competitor names are confirmed in public sources.

Sources

1. [LinkedIn] Ebenbuild | https://de.linkedin.com/company/ebenbuild
2. [mtec-sc.org] Ebenbuild | https://mtec-sc.org/life-sciences/ebenbuild
3. [Crunchbase] Ebenbuild - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/ebenbuild
4. [VC Magazin, 2026] Ebenbuild funding | https://www.vc-magazin.de/
5. [Munich Startup, 2026] Ebenbuild - Munich Startup | https://www.munich-startup.de/en/startups/ebenbuild/
6. [BioM, 2026] Ebenbuild funding | https://www.biom.org/
7. [tum.de, 2026] Ebenbuild founding | https://www.tum.de/
8. [BioWorld, 2026] Ebenbuild aims to transform lung care with digital twin tech | https://www.bioworld.com/articles/726762-ebenbuild-aims-to-transform-lung-care-with-digital-twin-tech
9. [htgf.de] Ebenbuild portfolio page | https://www.htgf.de/en/portfolio/htgffamily/ebenbuild/
10. [Munich Startup] Ebenbuild receives EIC funding | https://www.munich-startup.de/en/111702/ebenbuild-eic-funding/
11. [Mirage News, 2026] Ebenbuild validation study | https://www.miragenews.com/
12. [PharmiWeb.com, 2026] Ebenbuild roadmap | https://www.pharmiweb.com/
13. [Precedence Research, 2024] Clinical Decision Support Systems Market | https://www.precedenceresearch.com/clinical-decision-support-systems-market
14. [Future Market Insights, 2024] Digital Twin Market in Healthcare | https://www.futuremarketinsights.com/reports/digital-twin-market-in-healthcare
15. [PubMed, 2023] ARDS mortality | https://pubmed.ncbi.nlm.nih.gov/
16. [FDA, 2023] FDA guidance on modeling and simulation | https://www.fda.gov/
17. [DDW-Online, 2026] Ebenbuild technology validation | https://www.ddw-online.com/
18. [Grand View Research, 2023] Clinical Decision Support Systems Market | https://www.grandviewresearch.com/industry-analysis/clinical-decision-support-systems-market
19. [Reuters, 2021] HeartFlow valuation | https://www.reuters.com/